Foli Bio

United States
New York City, New York, United States, 11101

Company profile

Foli Bio company profile

Foli Bio is a precision medicine company transforming gastrointestinal disease diagnosis and drug development through Foli-seq, a novel non-invasive gut transcriptomics platform. By decoding exfoliated human RNA from stool, Foli-seq delivers deep mechanistic insight into inflammation, barrier dysfunction and treatment response. We are building a scalable insight engine that not only powers our internal diagnostic programs and partnered biomarker discovery across pharma pipelines but also serves as the foundation for AI-driven prediction, stratification, and patient monitoring. Ultimately, Foli-seq is positioned to evolve into a domain-specific foundation model for gut diseases.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Founded
2023-01-01, Year

Headquarters

Postal code
11101
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
5
Total equity funding
$1M
Last funding
Grant / $305,000 / 2025-07-25
Last equity funding
Seed / $1M
Investors
5
Lead investors
1
Articles
1

Founders and investors

Lead investors

Undisclosed Investor

Investors

Bristol-Myers SquibbColumbia Technology VenturesNational Institute of HealthNational Science FoundationUndisclosed Investor